Journal of
Translational Regenerative Medicine

2026. Volume 1

Editorial

Pioneering a Multidisciplinary Frontier in Regenerative Medicine: Vision, Scope, and the Path Ahead

Mostafa Shahrezaee[1*]

1. Trauma and Surgery Research Center, AJA University of Medical Science, Tehran, Iran.

Use your device to scan and read the article online

Citation Shahrezaee M. Pioneering a Multidisciplinary Frontier in Regenerative Medicine: Vision, Scope, and the Path Ahead. Journal of Translational Regenerative Medicine. 2025; 1:E1. http://dx.doi.org/10.32598/JTRM.1.1

http://dx.doi.org/10.32598/JTRM.1.1

Introduction

Multidisciplinary vision and scope

This editorial sets the stage for the Journal of Translational Regenerative Medicine (JTRM) by highlighting the convergence of diverse disciplines, including biology, engineering, clinical, and surgical sciences. Regenerative medicine inherently demands cross-disciplinary collaboration. True innovation emerges where clinicians, biotechnologists, tissue engineers, pharmacologists, and molecular scientists converge. This breakdown of traditional silos underscores a critical truth: Complex healthcare challenges cannot be solved in isolation. By building bridges across disciplines, JTRM positions itself at the forefront of this integrative movement in biomedical science.

Personalized and translational focus

JTRM's vision embraces the evolution of personalized regenerative therapies and translational science. Breakthroughs in technologies such as CRISPR-Cas9 and induced pluripotent stem cells (iPSCs) are enabling treatments tailored to individual genetic profiles. iPSC technology, in particular, is transforming in vitro research and holds immense promise for advancing patient-specific regenerative approaches. The editorial also emphasizes the journal's commitment to facilitating the lab-to-clinic transition, thereby bridging the gap between innovation and implementation. The recent global surge in regenerative clinical trials reflects this momentum, reinforcing the urgency of translational efforts that JTRM is poised to support.

Ethical, regulatory, and logistical challenges

Acknowledging the ethical, regulatory, and logistical barriers to implementing regenerative medicine is a hallmark of responsible editorial leadership. From stem cell sourcing to gene editing, safety standards to approval pipelines, the editorial signals that JTRM will not shy away from these complex discussions. Instead, it aims to foster dialogue on responsible translation, standardization, and global regulatory cooperation. Mentioning broader international frameworks, such as the FDA's RMAT (regenerative medicine advanced therapy) designation, reminds readers that the path forward includes governance as much as innovation. JTRM will serve as a forum to navigate these challenges with transparency and accountability.

*** Corresponding Author:**
Mostafa Shahrezaee, MD.
Address: *Trauma and Surgery Research Center, AJA University of Medical Science, Tehran, Iran.*
Phone: *+98 (912) 535 3974*
E-mail: *moshahrezayee@yahoo.com*

Invitation to collaboration and innovation

This editorial closes with an open call to researchers, engineers, clinicians, and innovators to make JTRM their scientific home. By providing a multidisciplinary platform, JTRM commits to accelerating collaboration and knowledge transfer. Studies consistently show that multidisciplinary research leads to higher-impact publications and faster clinical translation. This inclusive and optimistic tone is precisely what a pioneering journal requires: One that not only welcomes diversity of thought but actively cultivates it.

Conclusion

In summary, the editorial effectively articulates JTRM's vision: To serve as a multidisciplinary hub for translating regenerative discoveries into clinical realities. It presents a grounded yet aspirational roadmap, poised to attract contributors across the full spectrum of science and medicine. Through convergence, innovation, and translational rigor, JTRM aims to be at the forefront of the next generation of regenerative breakthroughs.